{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:31:58Z","timestamp":1740130318869,"version":"3.37.3"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Eli Lilly"},{"name":"2020 New Horizon Fellowship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The alternative ASDAS (altASDAS) is an index that can be used when patient global assessment is unavailable. Our aim was to test the truth and discrimination aspects according to OMERACT filter 2.0 of the altASDAS in an external cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Cohorts from the COAST trials of ixekizumab (COAST-V, -W, -X; 16-week primary endpoint) enrolling radiographic\/non-radiographic axial SpA patients were pooled. The ASDAS [original formula with patient global assessment (PGA)] and altASDAS were calculated. Truth was assessed by agreement with the continuous ASDAS [intraclass correlation coefficients (ICCs)] and ASDAS disease activity (DA) states (weighted \u03ba), Bland\u2013Altman plots [mean difference (MD) and 95% limits of agreement (LoA)] and Pearson\u2019s correlations between altASDAS\/ASDAS and other constructs. Discrimination was tested by the ability of altASDAS to distinguish high\/low DA according to nocturnal pain &amp;gt;6\/10 as an external anchor and agreement (\u03ba) with ASDAS in major improvement (MI) and clinically important improvement (CII).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 958 patients were included. For truth, agreement with ASDAS was very good (ICC\u2009=\u20090.99, \u03ba\u2009=\u20090.91), MD with ASDAS was 0.03 (95% LoA \u22120.31\u20130.24) and correlation coefficients of altASDAS with related constructs were within a prespecified 0.3-wide band around those between ASDAS and the same construct. For discrimination, the altASDAS discriminated between DA states and agreed with ASDAS response (\u03ba MI\u2009=\u20090.91, CII\u2009=\u20090.93).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The altASDAS was truthful and discriminative in an external cohort and as such has been fully validated to be used in cases when PGA is unavailable.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac618","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T17:53:58Z","timestamp":1666720438000},"page":"2257-2261","source":"Crossref","is-referenced-by-count":0,"title":["External validation of the alternative Ankylosing Spondylitis Disease Activity Score in three randomized clinical trials of ixekizumab"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-0939","authenticated-orcid":false,"given":"Augusta","family":"Ortolan","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden, The Netherlands"},{"name":"Rheumatology Unit, Department of Medicine, University of Padova, DIMED , Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden, The Netherlands"},{"name":"Department of Rheumatology, Zuyderland Medical Center , Heerlen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-8873","authenticated-orcid":false,"given":"Roberta","family":"Ramonda","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, University of Padova, DIMED , Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"key":"2023060113241533400_keac618-B1","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023060113241533400_keac618-B2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023060113241533400_keac618-B3","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2023060113241533400_keac618-B4","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/rheumatology\/keaa241","article-title":"Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable","volume":"60","author":"Ortolan","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2023060113241533400_keac618-B5","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/rheumatology\/kez480","article-title":"How to calculate the ASDAS based on C-reactive protein without individual questions from the BASDAI: the BASDAI-based ASDAS formula","volume":"59","author":"Aranda-Valera","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2023060113241533400_keac618-B6","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1093\/rheumatology\/keaa690","article-title":"Comment on: Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable","volume":"60","author":"Aranda-Valera","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2023060113241533400_keac618-B7","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jclinepi.2013.11.013","article-title":"Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0","volume":"67","author":"Boers","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"2023060113241533400_keac618-B8","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"2023060113241533400_keac618-B9","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023060113241533400_keac618-B10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"2023060113241533400_keac618-B11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/art.38921","article-title":"Calculating the ankylosing spondylitis disease activity score if the conventional c-reactive protein level is below the limit of detection or if high-sensitivity C-reactive protein is used: an analysis in the DESIR cohort","volume":"67","author":"Machado","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2023060113241533400_keac618-B12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs","volume":"31","author":"McHorney","year":"1993","journal-title":"Med Care"},{"key":"2023060113241533400_keac618-B13","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/annrheumdis-2013-203967","article-title":"Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS","volume":"74","author":"Kiltz","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023060113241533400_keac618-B14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/BOR.0b013e3283470f23","article-title":"How to measure disease activity in axial spondyloarthritis?","volume":"23","author":"Machado","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"2023060113241533400_keac618-B15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2023060113241533400_keac618-B16","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states","volume":"77","author":"Machado","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023060113241533400_keac618-B17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3899\/jrheum.181040","article-title":"Disease activity cutoff values in initiating tumor necrosis factor inhibitor therapy in ankylosing spondylitis: a German GO-NICE study subanalysis","volume":"47","author":"Braun","year":"2020","journal-title":"J Rheumatol"},{"key":"2023060113241533400_keac618-B18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12891-020-03941-8","article-title":"Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study","volume":"22","author":"Nam","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"key":"2023060113241533400_keac618-B19","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3899\/jrheum.151244","article-title":"The minimum clinically important improvement and patient-acceptable symptom state in the BASDAI and BASFI for patients with ankylosing spondylitis","volume":"43","author":"Kviatkovsky","year":"2016","journal-title":"J Rheumatol"},{"key":"2023060113241533400_keac618-B20","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1093\/rheumatology\/keaa688","article-title":"Comment on: Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable: reply","volume":"60","author":"Ortolan","year":"2021","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac618\/46972609\/keac618.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/6\/2257\/50500735\/keac618.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/6\/2257\/50500735\/keac618.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T13:33:08Z","timestamp":1685626388000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/6\/2257\/6772504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,10,25]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac618","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"type":"print","value":"1462-0324"},{"type":"electronic","value":"1462-0332"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2022,10,25]]}}}